New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
08:31 EDTNVAXNovavax says BARDA continues contract for both seasonal, pandemic flu programs
Novavax announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority, or BARDA, has completed an In-Process Review of Novavax' contract covering the company's recombinant virus-like particle vaccine candidates for pandemic and seasonal influenza. The contractually-defined IPR was conducted by a team of U.S. Government experts, who provided input on Novavax' progress during the contract base period and plans for further development, including both near-term process development and manufacturing activities and longer-term clinical efforts. BARDA has notified the company that based on the results of the IPR, a milestone decision has been made to continue the contract for both the seasonal and pandemic influenza programs. In March 2011, Novavax was awarded a contract valued at up to $179M by BARDA for the advanced development of recombinant vaccines for the prevention of seasonal and pandemic influenza. In the midst of the contract's 3-year base period, valued at $97M, Novavax has been developing and testing its novel recombinant virus-like particle influenza vaccines to address BARDA's commitment to advancing recombinant-based technology as a component of pandemic preparedness. The contract can be extended for an additional 24-month option period at BARDA's option, with $82M in additional funding to build on the work Novavax accomplishes during the base period and to support manufacturing scale-up and licensure by the U.S. Food & Drug Administration.
News For NVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
13:43 EDTNVAXUSDA says bird flu found in backyard poultry in Oregon
The United States Department of Agriculture’s Animal and Plant Health Inspection Service confirmed the presence of highly pathogenic H5N8 avian influenza in guinea fowl and chickens from a small backyard poultry flock in Winston, Oregon. The H5N8 virus has not been found in commercial poultry anywhere in the United States and there is no immediate public health concern, as the H5N8 virus has been found in birds in other parts of the world and has not caused any human infection to date, the USDA stated. The Fly notes companies that offer or are developing flu vaccines include BioCryst (BCRX) and Novavax (NVAX). Publicly traded meat producers include Hormel Foods (HRL), Pilgrim's Pride (PPC), Sanderson Farms (SAFM) and Tyson Foods (TSN). Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use